Background Trapidil is an antiplatelet drug with specific platelet-derived growth factor antagonism and antiproliferative effects in the rat and rabbit models after balloon angioplasty.
Methods and Results
The Studio Trapidil versus Aspirin nella Restenosi Coronarica (STARC) is a multicentric, randomized, double-blind trial to assess the effects of trapidil in angiographic restenosis prevention after percutaneous transluminal coronary angioplasty (PTCA). Patients received either trapidil 100 mg TID or aspirin at the same dosage at least 3 days before angioplasty and for 6 months thereafter. Coronary angiograms before PTCA, after PTCA, and at 6-month follow-up were quantitatively analyzed with manual calipers. Of the initial 384 patients recruited, 254 were evaluable for restenosis analysis (128 trapidil, 126 aspirin). Restenosis, defined as a loss of initial percent gain after PTCA of at least R ecurrence of stenosis after percutaneous trans- luminal coronary angioplasty (PTCA) is still the major limitation of the long-term clinical success of this procedure. Restenosis varies in most series from 30% to 40% but may be as high as 50%.
Recent publications about the physiopathology of restenosis'-5 assign a major role to vascular smooth muscle cell (VSMC) migration and proliferation in response to the chemotactic substances released by the damaged intimal surface and platelets. Among these, platelet-derived growth factor (PDGF) seems to play an important role, not only as a powerful mitogen for VSMCs but also as a mediator for the inflammatory response secondary to the stress of balloon inflation.6 Therefore, some of the efforts toward preventing post-PTCA restenosis have been to reduce PDGF activity with monoclonal antibodies or trapidil. Trapidil (triazolopyrimidine), also a thromboxane A2 inhibitor,7 exerts its effect via a competitive PDGFreceptor blockade. 
Methods

Study Population
All consecutive patients scheduled for PTCA with an angiographically documented, functionally significant stenosis in one or more principal coronary arteries were considered for inclusion in six clinical centers (see "Appendix"). Between April 1990 and May 1992, 384 patients who met the inclusion and exclusion criteria listed below were recruited.
The trial was carried out according to the declaration of Helsinki, and all patients gave informed consent to the study. Patients with a previous myocardial infarction or thrombolytic therapy <15 days earlier were excluded from the study. Total occlusions were also excluded because success and restenosis rate are known to be significantly worse than in nonocclusive lesions. Patients with restenotic lesions were not eligible in the study because of the potentially different biological substrate they represent. Other criteria for exclusion were inability to return for repeat angiogram; Q-wave infarct or akinesia at all sites considered for PTCA; three-vessel or left main coronary disease; women of childbearing potential; hepatic or renal insufficiency; known intolerance to trapidil or ASA; and active peptic disease.
Randomization and Treatment Protocol
Patients were randomly assigned to trapidil or ASA at least 3 days before the procedure. Only four procedures (two in both groups) were considered to be angiographically unsuccessful (post-PTCA stenosis >50%). In 75 cases, exclusion criteria were overlooked and patients withdrew from the study ( Table 1) . Three hundred five patients form the intention-totreat population of the study. Of these patients, 21 had to stop treatment because of adverse events, 7 violated protocol, and 23 refused follow-up angiography, so that the per-protocol population consists of 254 patients (Fig 1) .
The treatment consisted of three capsules of trapidil, 100 mg each, every 8 hours or matched ASA, 100 mg TID. Treatment ceased 6 months after PTCA.
Concomitant treatments permitted were calcium antagonists, nitrates, 3-blockers, and paracetamol; not allowed were salicylates or other nonsteroidal anti-inflammatory drugs, steroids, angiotensin-converting enzyme inhibitors, heparin (after >24 hours post-PTCA), and warfarin. 
Follow-Up Protocol
PTCA Procedure and Angiographic Analysis
At the beginning of the procedure, 10 000 IU heparin was administered intravenously as a bolus. At the completion of the procedure, a continuous infusion of 1000 IU heparin IV was started and continued at a dosage sufficient to maintain activated partial thromboplastin time between two and three times basal values. Choice of balloon type, inflation duration, and pressure were left to the operator.
For the purpose of the study, three coronary angiograms for each patient were obtained: one just before PTCA, one immediately after PTCA, and a third at the 6-month followup. Efforts were made to keep the angiographic views of the same patient constant. At the end of the PTCA, the initial gain was calculated (initial stenosis minus residual stenosis). After control angiography, final gain and loss of gain were obtained (initial stenosis minus final stenosis and initial gain minus final gain).
Recurrence was defined as the loss of at least 50% of the gain in luminal diameter accomplished by dilatation (initial gain minus final gain/initial gainxlO0). Restenosis was also evaluated by the definition of a final stenosis as .50%.
Other angiographic parameters recorded were length, eccentricity, presence of calcifications, and collateral blood flow.
To validate the method of angiographic analysis, 20 pre-and post-PTCA stenoses in each treatment arm were measured twice at different times by two different operators. Interindividual and intraindividual differences were compared by Student's t test and linear regression analysis. Mean percent pre-PTCA stenosis was 79.1+9.8% and 78.5 ±9.9% for the first observer versus 78.9±8.9% and 79.1±9.2% for the second in the two different measurements. Both interobserver and intraobserver P values were nonsignificant. Correlation coefficients were .851 interobserver and .949 and .943 intraobserver for the first and the second operators, respectively (P<.001). Mean percent post-PTCA stenosis results were 23.8±10.0% and 24.0±9.9% for the first observer versus 25.4±8.7% and 25.0±9.1% for the second. Interobserver and intraobserver P values were nonsignificant. Correlation coefficients were .715 interobserver and .881 and .913 intraobserver for the first and the second operators, respectively (P<.001).
End Points
The primary end point was restenosis at the follow-up coronary angiography. Any individual patient was considered to have restenosis if at least one vessel dilated was restenotic even if the other dilated lesions were not. Any lesion that showed a loss of initial gain >50% was considered a restenosis.
Secondary end points were clinical: occurrence of acute (72 hours) closure, acute myocardial infarction, coronary bypass surgery, and recurrence of angina at follow-up. Unstable angina was defined as angina at rest or crescendo effort angina. The results of angiographic analysis are listed in Table 5 . Initial and residual stenosis and initial gain were comparable in the two groups, while a statistically significant difference was noted for final gain and loss of gain in favor of the T group. The cumulative distribution curves of initial, residual, and final stenosis in the two treatment arms are shown in Fig 2. Restenosis per patient, defined as loss of initial gain 250%, occurred in 31 of 128 patients (24.2%) in the T group and in 50 of 126 patients (39.7%) in the ASA group (P<.01).
Restenosis per lesion results were 23.3% (34 of 142) in the T group and 36.9% (52 of 141) in the ASA group (P=.018) (Fig 3) .
By the second definition (final stenosis, >50%), restenosis per patient resulted in a 30.5% rate in the T group versus 45.2% in the ASA group (P=.015); restenosis per vessel was 29.6% in the T group versus 42.5% in the ASA group (P=.023) (Fig 4) . None of the risk factors analyzed correlated significantly with the incidence of restenosis except for unstable angina (Table 6) .
Clinical follow-up revealed a significantly lower incidence of angina at 6 months in the T group (25.8% versus 43.7%, P<.01), while other cardiovascular events were similar in the two groups (Table 7) . No deaths were observed in either group. There were no differences in laboratory tests between treatments both at baseline and at 6-month follow-up.
Nine patients suffered from acute events (5 in the T and 4 in the ASA group): 5 During the past 3 years, the role of QCA in the trials analyzing drugs for restenosis has been widely recognized, and the importance of the absolute values of minimal luminal diameter, absolute loss of gain, and gain index has been underlined, because they are more apt to describe a biological, continuous process such as restenosis.
The absence of normal gaussian-type distribution of follow-up cumulative distribution curves in our study must be attributed to the quantitative, but not automated, method of angiographic analysis used. The stenosis measurement with manual calipers yields results more similar to qualitative visual assessment than to computerized QCA. However, even if we are aware of the limitations in accuracy derived from a "semiquantitative" analysis, we must emphasize that we did not measure absolute dimensions, but only proportions, expressed as percentages, and that the errors of measurement must be evenly distributed among the two groups, since the reading of angiograms was blinded to treatment and done in a core laboratory.
Moreover, the clinical finding of a significant reduction in the incidence of angina in the T group opposed to that treated with ASA reinforces the validity of the angiographic results of this study.
In conclusion, trapidil has been shown to be effective in significantly reducing restenosis rate after coronary angioplasty in a randomized population. In addition, mean results for percent stenosis at follow-up, final gain, and loss of initial gain confirm its activity in preventing vessel reocclusion.
On the basis of previously reported trials, we think that a further study including a larger number of patients and with a higher dosage of trapidil is necessary to definitely validate trapidil efficacy in post-PTCA restenosis. We are presently projecting an international trial that will use trapidil 200 mg TID, at least 400 patients, and QCA analysis.
